1. Home
  2. CBZ vs ANAB Comparison

CBZ vs ANAB Comparison

Compare CBZ & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBIZ Inc.

CBZ

CBIZ Inc.

HOLD

Current Price

$32.94

Market Cap

1.7B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$62.89

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBZ
ANAB
Founded
1987
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
CBZ
ANAB
Price
$32.94
$62.89
Analyst Decision
Hold
Buy
Analyst Count
3
12
Target Price
$41.33
$71.67
AVG Volume (30 Days)
804.2K
567.5K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
134.62
91.02
EPS
1.83
N/A
Revenue
$922,003,000.00
$234,603,000.00
Revenue This Year
$3.92
N/A
Revenue Next Year
$4.12
$52.14
P/E Ratio
$17.82
N/A
Revenue Growth
7.79
157.01
52 Week Low
$24.29
$17.11
52 Week High
$77.91
$73.30

Technical Indicators

Market Signals
Indicator
CBZ
ANAB
Relative Strength Index (RSI) 67.77 51.98
Support Level $24.87 $53.46
Resistance Level $54.79 $69.56
Average True Range (ATR) 1.33 5.32
MACD 0.42 0.01
Stochastic Oscillator 85.38 64.47

Price Performance

Historical Comparison
CBZ
ANAB

About CBZ CBIZ Inc.

CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: